Health ConditionsNitric oxide (nitrogen monoxide) is a molecule and chemical compound with the chemical formula NO. In mammals including humans, it is a signaling molecule involved in several physiological and pathological processes. It is a powerful vasodilator with a half-life of a few seconds in the blood. The half-life of nitric oxide is generally considered to be approximately 3–6 seconds.
Nitric oxide is synthesized from L-arginine by nitric oxide synthase (NOS). As an endothelium-derived relaxing factor, a mediator of immune responses, a neurotransmitter, a cytotoxic free radical, and a signaling molecule, NO plays crucial roles in virtually every cellular and organ function in the body.
Such was the importance of this molecule to biomedical science that nitric oxide was proclaimed "Molecule of the Year" in 1992. Research into its function led to the 1998 Nobel Prize in Physiology or Medicine for elucidating the role of nitric oxide as a cardiovascular signalling molecule.
Synthesis of NO is catalyzed by a set of enzymes called nitric oxide synthases (NOS). L-arginine is the precursor for the synthesis of nitric oxide. The NO synthesis pathway involves both enzymatic (via NOS; the major pathway) and non-enzymatic pathways. L-arginine is converted to NO and citrulline in the presence of NADPH and oxygen.
NO is primarily formed by three isoenzymes in the endothelial cells—termed nitric oxide synthases (NOS). These isoenzymes consist of neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) nitric oxide synthases.
The NOS pathways depend on essential cofactors (tetrahydrobiopterin/BH4, FAD, FMN and heme) for their activity; NOS1 and NOS3 are also Ca²⁺ dependent. When the cofactor BH4 becomes limiting, eNOS becomes uncoupled: BH4 maintains eNOS in its functional dimeric form; in the absence of BH4, eNOS becomes uncoupled so that the electron flux is diverted away from the L-arginine binding site and instead reduces molecular oxygen, generating superoxide. This circumstance initiates a vicious cycle, wherein eNOS catalytic activity produces superoxide, not NO, worsening existing oxidative stress.
Other enzymes and compounds exhibiting redox potential, such as aldehyde oxidase, aldehyde dehydrogenase, carbonic anhydrase, vitamin C, and polyphenols, display the ability to synthesize NO from nitrite (NO₂⁻) reduction. This represents a distinct, non-enzymatic pathway for NO generation, particularly relevant when dietary nitrate is consumed.
NO is an important regulator and mediator of numerous processes in the nervous, immune, and cardiovascular systems. These include vascular smooth muscle relaxation, resulting in arterial vasodilation and increasing blood flow. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic-GMP (cGMP).
In addition to antihypertensive and antithrombotic actions, eNOS-derived NO also possesses multiple anti-atherosclerotic properties, including prevention of leukocyte adhesion to vascular endothelium and leukocyte migration into the vascular wall, inhibition of LDL oxidation, and inhibition of vascular smooth muscle cell proliferation.
NO is also a neurotransmitter and has been associated with neuronal activity and various functions such as avoidance learning. Nitric oxide has been identified as an important neurotransmitter substance involved in the pathophysiology of many neurological disorders, such as epilepsy, schizophrenia, drug addiction, anxiety, and major depression.
NO also partially mediates macrophage cytotoxicity against microbes and tumor cells. NO derived from iNOS appears to be a proinflammatory mediator with immunomodulatory effects. At physiological concentrations produced by eNOS and nNOS, NO exerts anti-inflammatory activity, whereas excessive production from iNOS under pathological conditions can contribute to tissue damage.
In the respiratory tract, NO is produced by a wide variety of cell types and is generated via oxidation of L-arginine catalyzed by NO synthase (NOS). NOS exists in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). The concentration of this molecule in exhaled air is abnormal in activated states of different inflammatory airway diseases, and its monitoring is potentially a major advance in the management of asthma.
In the female reproductive system, nitric oxide influences successive reproductive processes, such as ovulation, fertilization, embryo implantation, pregnancy maintenance, and delivery regulation. In the male reproductive system, nitric oxide affects progressive reproductive processes such as sperm maturation. Aspects of NO biology critical to gastrointestinal health and, consequently, nutritional status are increasingly being recognized, and attempts are underway to exploit the gastrointestinal actions of NO for therapeutic gain.
Recent studies suggest that eNOS-derived NO also promotes mitochondrial biogenesis, has antiobesogenic effects, and may be involved in the anti-aging effects and extension of lifespan induced by calorie restriction. Depletion of the eNOS gene induces hyperinsulinemia and insulin resistance. Nitric oxide is involved in a number of regulatory roles including cellular adaptation, energy balance, vascular health, anti-inflammatory signaling, immunity, hormonal, and nervous system functioning.
Reduced NO bioavailability with age stems from impaired endothelial and neuronal NO synthase activity, increased oxidative stress, and metabolic shifts that drive cardiovascular decline. The molecular mechanisms of aging-associated endothelial dysfunction are complex, but reduced nitric oxide bioavailability and altered vascular expression and activity of NOS enzymes have been implicated as major players. Impaired vascular relaxation in aging has been attributed to reduced eNOS-derived NO, while increased iNOS expression appears to account for nitrosative stress and disrupted vascular homeostasis.
Ageing has been proposed to be associated with increased levels of reactive oxygen species (ROS) that scavenge nitric oxide and thereby decrease the bioavailability of this vasoactive substance. The body's production and availability of NO decrease during ageing and in cardiovascular disease (CVD). This declined NO availability is associated with impaired blood vessel function, unresolved inflammatory responses, and an increased CVD risk.
Diets with a high saturated fat content induce high plasma fatty acid levels, and endothelial nitric oxide production is often impaired due to a reduction in nitric oxide synthase 3 phosphorylation. When analyzing results according to body mass index, ADMA levels were independently significantly higher and the L-arg/ADMA ratios were significantly lower in individuals with high BMI (≥26 kg/m²) compared with subjects with low BMI.
In animal research, endothelial function and serum nitric oxide began to decrease after six weeks on a high-fat diet (HFD), whereas elevated blood pressure and lipid peroxidation only began to increase at twelve weeks. This temporal pattern suggests that NO impairment may precede clinically measurable vascular changes.
High-fat-diet animals developed increased systolic blood pressure, aortic superoxide production, and impaired eNOS and endothelium-dependent relaxation. Nicotine further increased systolic blood pressure and superoxide production while further impairing eNOS in obese animals. The endothelial injury from cigarette smoke components appears to be mediated in part through NADPH oxidase activation and enhanced oxidative stress that scavenges available NO.
Asymmetric dimethylarginine (ADMA) is an arginine analogue that acts as an endogenous inhibitor of the NOS pathway. Loss of NO bioavailability due to reduced synthesis and increased scavenging by reactive oxygen species is a cardinal feature of endothelial dysfunction in vascular disease states. The pteridine cofactor tetrahydrobiopterin (BH4) has emerged as a critical determinant of eNOS activity: when BH4 availability is limiting, eNOS no longer produces NO but instead generates superoxide. In vascular disease states, there is oxidative degradation of BH4 by reactive oxygen species.
Evidence suggests that exercise training reduces oxidative stress and increases NO bioavailability in the endothelium of ageing humans. Skeletal muscle protein levels of endothelial and neuronal NO synthase were 32% and 24% higher, respectively, in older lifelong physically active subjects compared with older sedentary individuals. It is well established that NO bioavailability in conduit and resistance vessels can be enhanced by exercise training, particularly in populations who initially exhibit impaired NO function.
A lethal reaction can occur when a high amount of nitric oxide reacts with concurrently produced superoxide anions, generating highly toxic compounds such as peroxynitrite and hydroxyl radicals. Epidemiological and experimental studies have shown that increased superoxide production with advancing age causes oxidative stress and leads to endothelial dysfunction. Superoxide is a free radical that can rapidly scavenge NO directly, and this age-induced oxidative stress may contribute to the reduction of NO bioavailability.
Dietary nitrate provides a physiological substrate for nitric oxide production, which promotes vasodilatation, increases blood flow, and lowers blood pressure. Following the intake of nitrate, NO is produced in a pathway that involves commensal bacteria in the mouth. Dietary nitrate is concentrated by salivary glands, reduced to nitrite by oral commensal bacteria, swallowed, and further reduced to NO in the acidic environment of the stomach and systemically in the blood.
Several studies report beneficial effects of dietary nitrate sources as a new physiological, therapeutic, and nutritional approach to attain cardioprotective effects through NO production stimulation. High-nitrate vegetables include beetroot, spinach, rocket (arugula), celery, and lettuce. Compared to other nitrate-rich vegetables, beets have been shown to be a particularly practical choice because of their sensorial characteristics and easy formulations that facilitate patient adherence for long periods, allied to bioaccessibility and consequent effectiveness.
Definition and role: L-arginine is the main precursor of nitric oxide released from the vascular endothelium and serves as a key substrate for endothelial nitric oxide synthase (eNOS).
Traditional Use: L-arginine as a defined nutritional supplement does not have a classical herbal or traditional medicine history. Its identification as a dietary amino acid and NOS substrate emerged from 20th-century biochemical research rather than from a pre-scientific healing tradition.
Scientific Evidence: Supplemental arginine has shown promise as a safe therapeutic option to improve endogenous nitric oxide regulation in cardiovascular diseases associated with endothelial dysfunction. L-arginine, an endogenous amino acid, was reported in clinical studies in adults to improve cardiovascular function in hypertension, pulmonary hypertension, pre-eclampsia, angina, and MELAS syndrome.
Oral L-arginine supplementation has been used in several studies to improve endothelium-dependent, NO-mediated vasodilation. L-arginine treatment is hampered by extensive presystemic elimination due to intestinal arginase activity. In acute human studies, oral supplementation of L-arginine results in the improvement of endothelium-dependent forearm vasodilation in subjects with pre-existing hyperlipidemia.
Evidence limitations: Of forty-four completed registered trials examining arginine or citrulline and blood pressure as a primary endpoint, only five were included for analysis in one systematic review. Inconsistencies in study design pose a challenge for systematic reviews and meta-analyses to accurately assess the effect size and impact of L-arginine or L-citrulline on blood pressure.
Traditional Use: L-citrulline is found naturally in watermelon (Citrullus lanatus), which has a long culinary tradition but was not specifically used historically as a nitric oxide precursor; its role as such was established only through modern pharmacological research.
Scientific Evidence: L-citrulline, a natural precursor of L-arginine, is more bioavailable than L-arginine because of hepatic first-pass metabolism avoidance and longer circulation time. Oral L-citrulline supplementation raises plasma L-arginine concentration and augments NO-dependent signalling in a dose-dependent manner.
In a pharmacokinetic crossover study in healthy volunteers with elevated ADMA: the highest dose of citrulline (3 g twice daily) increased the minimum plasma L-arginine concentration and improved the L-arginine/ADMA ratio from 186 ± 8 (baseline) to 278 ± 14 (P < 0.01). Urinary nitrate and cGMP were also significantly increased.
In a controlled crossover study of patients with MELAS syndrome: supplementation with citrulline resulted in more significant increases in nitric oxide production rate, arginine and citrulline flux, and plasma arginine concentrations. Citrulline supplementation increased plasma arginine concentration from 57.6±2.1 to 182.0±14.4 μmol/L, compared to arginine supplementation which raised it from 57.1±3.2 to 143.8±9.9 μmol/L.
Evidence limitations: Clinical trial evidence for chronic blood pressure outcomes remains inconsistent. Most human trials are small, short-term, and use heterogeneous populations, limiting generalizability.
Traditional Use: Beetroot (Beta vulgaris) has been used in European folk medicine for centuries as a blood-building tonic and for liver complaints, though its specific connection to nitric oxide production was not understood prior to modern biochemistry.
Scientific Evidence: Single dose administration of dietary inorganic nitrate acutely reduces blood pressure in normotensive healthy volunteers, via bioconversion to the vasodilator nitric oxide.
In a landmark double-blind, placebo-controlled RCT: 68 patients with hypertension were randomly assigned to receive daily dietary supplementation for 4 weeks with either dietary nitrate (250 mL daily as beetroot juice) or placebo (nitrate-free beetroot juice) after a 2-week run-in period. Stratified randomization included drug-naive (n=34) and treated (n=34) patients aged 18–85 years. In this largest randomized controlled trial of 68 hypertensive patients, nitrate-replete beetroot juice reduced systolic blood pressure by a mean of 9.0 ± 7.8 mm Hg after 4 weeks compared to 0.1 ± 8.0 mm Hg in the nitrate-deplete group.
In a double-blind, randomized, placebo-controlled crossover trial in fifteen healthy normotensive adults: following a washout period, the procedure was repeated with crossover. Compared with placebo, ingestion of beetroot juice containing nitrate lowered aortic systolic blood pressure at 30 minutes by 5.2 (95% CI: 1.9–8.5) mmHg.
A systematic review of RCTs published between 2008 and 2018 identified 11 eligible studies: this review demonstrated that beetroot juice supplementation is a cost-effective strategy that may reduce blood pressure in different populations, probably through the nitrate/nitrite/nitric oxide pathway and secondary metabolites found in Beta vulgaris.
Evidence limitations: Dosage, supplementation regimen, and individual health status must be considered to obtain the maximum cardioprotective effect following nitrate intake. Most trials are short-term; long-term efficacy and safety data in diverse populations remain limited.
Traditional Use: Garlic has a centuries-long history of use across Mediterranean, Ayurvedic, and Traditional Chinese Medicine systems for cardiovascular complaints, infections, and general vitality. Traditional preparations include raw consumption, decoctions, and aged fermented extracts. These uses long predate any understanding of nitric oxide biology.
Scientific Evidence: Many medicinal plants and their secondary metabolites, including garlic, are potentially involved in cardiovascular prevention through increasing NO bioavailability and decreasing endothelium dysfunction. Compounds in garlic, including allicin and S-allyl-L-cysteine, act as hydrogen sulfide (H₂S) donors, and H₂S may promote NO synthesis through eNOS-dependent and enterosalivary pathways to maintain elevated cGMP levels.
In a pilot human study: the investigation was carried out to determine the in vivo effects of garlic and antioxidants on marginally high blood pressure in human subjects as well as in vitro effects on human endothelial cell NO production. Vitamin C alone (2.0 g/d), garlic alone (2.5 g/d), or a combination was administered for 10 days in human subjects with marginally high blood pressure. Vitamin C alone did not result in any changes in systolic or diastolic blood pressure, whereas garlic resulted in a significant lowering (P < .05) of mean systolic blood pressure.
In an in vitro model, alliin (a compound derived from garlic) significantly increased (P < 0.01) nitric oxide release, which was further enhanced by vitamins C and E.
Evidence limitations: Human evidence for garlic's direct effects on NO specifically remains largely limited to small pilot studies and in vitro models. The active compounds (allicin, S-allyl cysteine, H₂S precursors) vary by garlic preparation, making standardization and dose-response characterization difficult. Larger well-controlled trials are needed.
Traditional Use: Red wine has been consumed in Mediterranean cultures since antiquity and associated empirically with cardiovascular benefit long before resveratrol or flavanols were identified. Cocoa beverages were used by Mesoamerican civilizations and later adopted globally. Green and black teas have been integral to East Asian and South Asian health traditions for millennia. None of these traditions specifically identified polyphenols or NO modulation as the mechanism of benefit.
Scientific Evidence: Compounds of natural origin such as polyphenols, which are obtainable through diet, have been widely studied in in vivo and in vitro investigations for their ability to induce or inhibit NO release, depending on the tissue.
Resveratrol: Resveratrol stimulates NO production from eNOS by a number of mechanisms, including upregulation of eNOS expression, stimulation of eNOS enzymatic activity, and reversal of eNOS uncoupling. In addition, by reducing oxidative stress, resveratrol prevents oxidative NO inactivation by superoxide, thereby enhancing NO bioavailability. It activates MAPK and eNOS at nanomolar concentrations — concentrations possibly transiently achieved in serum following oral red wine consumption. However, bioavailability of resveratrol following oral dosing in humans is low and variable; robust human clinical evidence for NO-mediated outcomes specifically remains preliminary.
Cocoa Flavanols: Flavanol-containing foods, especially cocoa and cocoa-derived products, have demonstrated blood pressure-lowering effects in both humans and animals. These effects could be related to the maintenance of optimal NO levels and could be associated with lowering superoxide anion production. A study has documented that vasodilation was the main effect observed as a consequence of NO release following cocoa ingestion. Improvement of endothelial function was higher in older (>50 years) than in younger (<50 years) healthy individuals, as assessed by flow-mediated dilation.
Other polyphenols and plant extracts: Other dietary products and their active components known to activate eNOS include cocoa (OPC and epicatechin), pomegranates (polyphenols), black and green tea (flavonoids, especially epigallocatechin gallate), olive oil (oleic acid and polyphenols), soy (genistein), and quercetin. In addition, phytomedical preparations made from ginkgo, hawthorn, and ginseng have been shown to affect endothelial NO production.
Evidence limitations: The majority of polyphenol research on NO pathways comes from in vitro cell culture studies and animal models. Human clinical trials are generally small, heterogeneous, and short-term. Bioavailability of most isolated polyphenols after oral ingestion is highly variable. No polyphenol has been definitively established as a clinically significant NO modulator in humans through large-scale RCTs.
Traditional Use: Ginseng (Panax ginseng) root has been used for over 2,000 years in Traditional Chinese Medicine as an adaptogen, tonic, and remedy for fatigue, sexual dysfunction, and systemic weakness. Traditional use did not relate to NO biology.
Scientific Evidence: Comparing NO-releasing and eNOS-activating potency of various ginseng extracts and individual ginsenosides in human umbilical vein endothelial cells, the protopanaxatriol-enriched extract had the highest potency in NO production, followed by crude extract. Treatment resulted in rapid activation of intracellular signaling pathways, immediate linear rise of NO, and increased eNOS activation. Despite a large array of data for individual ginsenosides, the main active ginseng component contributing to vascular endothelium relaxation still remains uncertain.
Evidence limitations: Research is predominantly in vitro. Clinical human evidence for ginseng specifically enhancing NO-mediated outcomes is limited and preliminary.
Traditional Use: Vitamin C from citrus and other fruits has been used empirically to treat scurvy and promote vascular health since at least the 18th century, though the biochemical mechanisms were unknown.
Scientific Evidence: Research suggests that a beneficial effect of vitamin C on endothelial function is best explained by increased intracellular BH4 content and subsequent enhancement of eNOS activity. Vitamin C may prevent endothelial dysfunction by scavenging free radicals and increasing the bioavailability of nitric oxide. In vitro studies measuring L-citrulline formation (a marker of eNOS enzymatic activity) found it was significantly increased in cells treated for 24 hours with vitamin C.
In animal ischemia models: dietary co-supplementation with tetrahydrobiopterin, L-arginine, and vitamin C acts synergistically to decrease oxidative stress, increase nitric oxide, and improve perfusion. In ischemic conditions, decreased NO bioavailability was observed because of increased oxidative stress combined with decreased L-arginine and tetrahydrobiopterin.
Evidence limitations: Most mechanistic evidence for vitamin C and NO is from in vitro and animal models. Human clinical trials specifically isolating vitamin C's effect on NO bioavailability are limited, and results are not uniformly positive across studies. Vitamin C alone did not lower blood pressure in at least one human pilot study examining NO-mediated effects.
Traditional Use: Folate-rich foods (dark leafy greens, legumes) have traditional dietary roles in many cultures, but folic acid as a defined supplement targeting eNOS is a modern clinical concept.
Scientific Evidence: Recent evidence suggests that nitric oxide-dependent vasodilation in aged adults is improved through chronic ingestion of folic acid, an essential vitamin that improves the vasodilatory response through a direct interaction with endothelial nitric oxide synthase and/or an indirect restoration of BH4 availability. Folic acid's active metabolite, 5-methyltetrahydrofolate (5-MTHF), can directly bind (at the BH4 docking site) to endothelial nitric oxide synthase.
Folic acid prevents uncoupling of endothelial nitric oxide synthase by promoting recycling of tetrahydrobiopterin due to restoration of dihydrofolate reductase expression. In cell culture studies using human umbilical vein endothelial cells, folic acid treatment significantly increased BH4 levels and NO production while reducing homocysteine levels (P < 0.001 vs. paired homocysteine group).
5-methyltetrahydrofolate (MTHF), the active form of folic acid, has been reported to restore NO status in hypercholesterolemic patients.
Evidence limitations: Most robust data are from cell culture and animal models. Human clinical trials specifically on folic acid and NO outcomes are limited in scale. The effect may be most relevant in individuals with elevated homocysteine or compromised BH4 recycling.
Increasing evidence shows that many dietary factors, including protein, amino acids, glucose, fructose, cholesterol, fatty acids, vitamins, minerals, phytoestrogens, ethanol, and polyphenols, are either beneficial to health or contribute to the pathogenesis of chronic diseases partially through modulation of NO production by inducible NOS or constitutive NOS. Adherence to dietary patterns rich in green leafy vegetables and root vegetables naturally elevates dietary nitrate intake and may support the entero-salivary NO pathway.
Environmental factors such as temperature, exposure to sunlight, atmospheric humidity, water content and irradiation, as well as agricultural factors like plant genotype, fertilization, herbicide use, amount of available nitrogen, type of crop, soil conditions, and storage conditions all influence nitrate contents in plants.
Diets with a high saturated fat content induce high plasma fatty acid levels, and endothelial nitric oxide production is often impaired due to a reduction in nitric oxide synthase 3 phosphorylation. Animal research documents that a high-fat diet triggers impaired endothelium-dependent relaxation and reduced NO availability in the aorta.
It is well established that NO bioavailability in conduit and resistance vessels can be enhanced by exercise training, particularly in populations who initially exhibit impaired NO function. Skeletal muscle protein levels of endothelial and neuronal NO synthase were significantly higher in older lifelong physically active subjects compared with older sedentary individuals. Both aerobic and resistance exercise have been studied, with aerobic exercise showing the most consistent evidence for eNOS upregulation in humans.
Because the reduction of dietary nitrate to nitrite depends on commensal bacteria in the oral cavity, NO is produced in a pathway that involves commensal bacteria in the mouth following nitrate ingestion. Antiseptic mouthwash can disrupt oral bacteria populations and thereby impair this entero-salivary conversion. Research has demonstrated that use of antibacterial mouthwash can blunt the blood-pressure-lowering effect of dietary nitrate supplementation, though this evidence is primarily from small mechanistic studies.
While NO is a free radical, it has strong antioxidant and anti-inflammatory properties. This is because NO can interact with other free radicals, covalently oxidizing or neutralizing them. Conversely, a diet low in antioxidant nutrients (vitamins C and E, polyphenols) may permit higher levels of superoxide to accumulate, accelerating NO degradation to peroxynitrite. Diets high in antioxidant-rich foods are therefore considered conducive to maintaining NO bioavailability, though direct causal evidence in long-term human dietary trials is limited.
This compound contains an organic nitrate (–ONO2) functional group that releases nitric oxide via enzymatic reduction pathways identical to those of classical organic nitrate vasodilators. The amino acid ester backbone may improve membrane permeability for intracellular NO delivery. Its NO-releasing mechanism is established from the well-characterized organic nitrate pharmacology class.
Agmatine is the decarboxylation product of L-arginine that acts as an endogenous NOS modulator. It stimulates eNOS by binding imidazoline receptors on endothelial cells while inhibiting iNOS and nNOS, providing isoform-selective NO regulation that distinguishes it from simple NO precursors.
Arginine alpha-ketoglutarate (AAKG) is a salt of L-arginine and alpha-ketoglutaric acid used to deliver arginine as a NO precursor. A 7-day RCT showed AAKG significantly raised plasma L-arginine by ~85% but did not produce greater post-exercise NO or blood flow increases than placebo, indicating the arginine component drives any NO effect while independent benefit of the salt form is limited.
Arginine aspartate is a salt of L-arginine and aspartic acid; aspartate participates directly in the argininosuccinate synthase reaction regenerating arginine for eNOS-mediated NO synthesis. Preclinical data show aspartate combined with malate elevates L-arginine and NO production in hypertension models, complementing the established arginine-to-NO mechanism.
Arginine malate combines L-arginine with malic acid; malate supports the argininosuccinate-mediated arginine regeneration pathway and L-arginine is the direct eNOS substrate. Preclinical data show malate elevates L-arginine levels and NO production in hypertension models, giving the compound both direct substrate and metabolic recycling support for NO synthesis.
Arginine nitrate combines L-arginine with inorganic nitrate, providing NO production via two parallel pathways: the enzymatic eNOS-mediated arginine citrullination route and the non-enzymatic nitrate-nitrite-NO reduction cascade. This dual mechanism gives faster vasodilation onset than L-arginine alone and is used in sports and cardiovascular supplements.
Arginine silicate (Nitrosigine) is a patented arginine-silicon chelate shown in human RCTs to produce superior plasma arginine AUC and NO biomarker elevation compared to equivalent doses of L-arginine HCl. It enhances eNOS substrate delivery and is clinically studied for endothelial function support in sports and cardiovascular contexts.
ATP is an endothelium-dependent vasodilator that partly acts via nitric oxide (NO) pathways in human vasculature. Intra-arterial infusion studies in humans show that ATP-induced limb vasodilation is partially (approximately 14–40%) mediated by nitric oxide synthase activation, with P2Y receptors on the endothelium activating eNOS. The relationship is mechanistically established in humans, though oral supplementation's effect on circulating NO levels is less directly documented.
Icariin enhances endothelial nitric oxide synthase (eNOS) expression and NO production in human endothelial cells in both short- and long-term studies. It also produces NO-dependent vasorelaxation in coronary arterial rings via eNOS/cGMP pathway activation. This NO-upregulating activity underpins many of Barrenwort's cardiovascular and erectogenic properties.
Beets are the most concentrated dietary source of inorganic nitrate (~250 mg/100 g), which is converted to NO via the nitrate-nitrite-NO pathway independent of NOS. Multiple RCTs show beetroot juice (300–500 mg nitrate) significantly raises plasma NO metabolites, lowers resting blood pressure by ~4–5 mmHg, and improves exercise performance.
Blueberry polyphenols increase nitric oxide bioavailability in human endothelial cells and in vivo by activating eNOS, reducing NADPH oxidase activity, and decreasing superoxide-mediated NO quenching. Plasma nitrite (NO2−) increases have been measured in human RCTs after blueberry consumption.
Cocoa flavanols (primarily epicatechin and procyanidins) activate eNOS via Akt/PI3K-dependent phosphorylation, raising NO production and improving flow-mediated dilation. Research in smokers shows 176–185 mg cocoa flavanols improve vascular dilation within 2 hours. Multiple RCTs and meta-analyses confirm cocoa flavanols reduce blood pressure and improve endothelial function through NO-mediated mechanisms.
CoQ10 supports nitric oxide (NO) bioavailability by protecting endothelial NO synthase (eNOS) from oxidative inactivation and reducing superoxide-mediated NO degradation. Clinical trials in type 2 diabetes and coronary artery disease patients show improved endothelium-dependent vasodilation (flow-mediated dilation) with CoQ10 supplementation. Evidence from NIH StatPearls lists improving endothelial function as a Level 2 clinical indication.
Cordyceps modulates nitric oxide (NO) signaling via stimulation of endothelial NOS (eNOS) activity. Cordycepin and adenosine in Cordyceps are reported to stimulate endothelial NO production, promoting vasodilation. This pathway is mechanistically linked to improvements in blood pressure and circulatory function observed in preclinical models.
EGCG, the primary catechin in green tea, increases eNOS phosphorylation, vascular cGMP, and BH4 levels while reducing oxidative stress in animal hypertension models. It is recognized among natural polyphenols that positively modulate eNOS activity and endothelial NO production in peer-reviewed literature.
Epicatechin, a flavan-3-ol in cocoa and tea, is among the dietary flavonoids most clearly shown to augment nitric oxide status in humans. A randomized crossover RCT found 200 mg epicatechin significantly raised plasma S-nitrosothiols, plasma nitrite, and urinary nitrate, and reduced endothelin-1 in healthy men, demonstrating enhanced endothelial NO production.
L-DOPA in fava beans is converted to dopamine, which stimulates endothelial nitric oxide synthase (eNOS) activity, increasing nitric oxide (NO) production. This mechanism contributes to vasodilation, blood pressure reduction, and improved vascular function. The dopaminergic pathway's influence on NO synthesis is documented in peer-reviewed cardiovascular literature.
Aged garlic extract activates constitutive NOS (eNOS) and temporarily raises plasma NO metabolites by 30–40% in vivo, independent of its arginine content. Garlic is recognized in peer-reviewed reviews among natural products that enhance endothelial NO production, with organosulfur compounds as the proposed active constituents.
Garlic's organosulfur compounds (DADS, DATS, SAC) stimulate endothelial nitric oxide synthase (eNOS), increasing NO bioavailability in vascular endothelium. This mechanism underlies garlic's antihypertensive and antiplatelet effects. Clinical trials using garlic with dietary nitrate have measured salivary NO increases in hypertensive subjects.
Panax ginseng ginsenosides stimulate eNOS in vascular endothelial cells via PI3K-Akt and AMPK signaling, increasing NO production. Systematic reviews of clinical trials confirm ginseng improves erectile function and vascular biomarkers through NO-mediated mechanisms, consistent with its multi-millennial cardiovascular use in Asian traditional medicine.
Ginsenosides are the primary bioactive triterpenoid saponins of Panax ginseng responsible for eNOS activation and increased endothelial NO production. Individual ginsenosides (Rg1, Re, Rb1) activate eNOS via PI3K-Akt, AMPK, and receptor-ligand pathways, with protopanaxatriol fractions showing the highest eNOS-activating potency in cell models.
Hawthorn extract (especially WS 1442) stimulates endothelial nitric oxide synthase (eNOS) to release NO from vascular endothelium, producing vasodilation and increasing coronary flow. This mechanism has been demonstrated in isolated arterial rings, rat heart preparations, and the human mammary artery. NO-mediated vasodilation is considered a primary mechanism behind hawthorn's cardiovascular and antihypertensive effects.
A 1999 peer-reviewed study (Tanner et al., Nitric Oxide journal) confirmed that gypenosides directly release nitric oxide in vitro. Multiple subsequent studies have linked jiaogulan's blood pressure and arterial effects to endothelial NO stimulation.
L-arginine is the direct endogenous substrate for nitric oxide synthase (NOS) enzymes, which convert it to NO and L-citrulline. Extensive peer-reviewed evidence confirms oral L-arginine supplementation increases NO synthesis and blood flow in tissues. Clinical studies demonstrate improvements in NO-dependent vasodilation, endothelial function, and blood pressure in populations with cardiovascular compromise.
L-citrulline is converted to L-arginine in the kidneys via the citrulline-NO cycle, making it a more bioavailable oral NO precursor than L-arginine itself. Clinical trials show it raises plasma arginine and NO metabolites more effectively than equivalent oral arginine doses. It is well-studied for endothelial function, blood pressure, and exercise performance.
L-ornithine is a urea cycle intermediate that supports NO production by feeding the ornithine-citrulline-arginine recycling pathway. Ornithine is converted to citrulline, which is then converted to arginine for eNOS-mediated NO synthesis, making it an indirect but metabolically established contributor to the arginine pool available for NO generation.
Diarginine malate delivers two molecules of L-arginine (the direct eNOS substrate) with malate (a Krebs cycle intermediate supporting arginine regeneration). Both components have established mechanistic relevance to NO synthesis: arginine as the NOS substrate and malate as a supporter of the argininosuccinate-mediated arginine recycling pathway.
Ornithine alpha-ketoglutarate (OKG) is metabolized to citrulline and arginine, supporting eNOS substrate availability and NO production. Clinically studied at 10–30 g/day in post-surgical and trauma patients, with arginine elevation and NO production proposed as contributing mechanisms to its documented wound healing and muscle metabolism benefits.
Peanuts are one of the richest dietary sources of L-arginine, the obligate substrate for endothelial nitric oxide synthase (eNOS). L-arginine supplementation in clinical studies increases NO production, improves flow-mediated dilation, and reduces arterial stiffness. This mechanistic pathway underlies peanuts' known cardiovascular and vascular benefits.
Pine bark extract (standardized as Pycnogenol from Pinus pinaster) stimulates eNOS transcription and activity, scavenges superoxide radicals that degrade NO, and has human clinical evidence for improved endothelial function and blood pressure, with documented synergy with L-arginine for NO-mediated improvements in erectile dysfunction.
Pomegranate polyphenols upregulate eNOS and protect nitric oxide from oxidative degradation, effectively increasing NO bioavailability. Human studies confirm improved arterial elasticity and blood pressure consistent with enhanced NO activity. Pomegranate is a dietary source of nitrates that feed the nitrate-nitrite-NO pathway.
Pycnogenol (French maritime pine bark extract) stimulates eNOS transcription and activity and scavenges superoxide that degrades NO, enhancing endothelial NO bioavailability. Human clinical studies show improved vascular function and blood pressure, and its combination with L-arginine has documented NO-mediated improvements in erectile dysfunction.
Quercetin is a plant flavonoid that augments nitric oxide status in humans by raising plasma S-nitrosothiols, plasma nitrite, and urinary nitrate while reducing endothelin-1 in a randomized crossover RCT. It is well characterized as a dietary polyphenol that activates eNOS and enhances endothelial NO production.
Resveratrol activates eNOS through AMPK/SIRT1-dependent phosphorylation and antioxidant superoxide scavenging, enhancing endothelial NO production and bioavailability. It is well documented in natural products and eNOS literature as a modulator of endothelial NO synthesis, with cardiovascular evidence consistent with NO-mediated vasodilation.
Spinach is among the most nitrate-dense vegetables, and dietary nitrate is the rate-limiting substrate for entero-salivary nitric oxide biosynthesis. RCTs confirm spinach intake significantly raises plasma nitrite and NO-related species, improving vascular function.
Taurine enhances endothelial nitric oxide bioavailability by stimulating endothelial nitric oxide synthase (eNOS), restoring redox balance, and increasing plasma hydrogen sulfide—an eNOS activator. This contributes to taurine's established vasodilatory and blood pressure-lowering effects demonstrated in clinical trials.
Preclinical and mechanistic studies demonstrate that tribulus saponins (protodioscin) promote endothelial nitric oxide release, causing vasodilation. This mechanism is proposed to underlie TT's pro-erectile and antihypertensive effects. In vitro confirmation of NO upregulation exists; direct human clinical measurement is lacking.
Ubiquinol increases nitric oxide (NO) bioavailability by enhancing superoxide dismutase (SOD) activity, thereby reducing superoxide-mediated NO degradation. A clinical RCT (n=51) found dose-dependent increases in serum NOx (nitric oxide metabolites) with 100–200 mg/day ubiquinol. This mechanism also underlies its blood pressure-lowering and arterial health effects.
Watermelon is among the richest natural sources of L-citrulline, which the body converts to L-arginine and then to NO via eNOS. Human studies show watermelon consumption and supplementation increase plasma arginine and NO bioavailability, improving blood pressure and endothelial function; concentrated extracts are needed to reliably achieve effective L-citrulline doses.
Go back